Shenzhen Salubris Pharmaceuticals Co Ltd (SZSE:002294) Share Price

Company Profile

Business description
Shenzhen Salubris Pharmaceuticals Co Ltd is a pharmaceutical company dedicated to the research, development, and sale of medical products for cardiovascular diseases, cephalosporins, and bone resorption inhibitors. Its products mainly focus on the areas of cardio-cerebral vascular disease, diabetes, complications, anti-tumor, and orthopedics. Its business lines include high-end chemical drugs, biological drugs, and medical devices. Its businesses are located in China, the United States, Germany, France, and Japan, and other countries and regions.
Contact
No. 6009, Shennan Avenue
37th Floor, Main Building, Tower B
Chegongmiao Greenview Plaza
Futian District
Shenzhen518040
CHN
T: +86 75583867888
https://www.salubris.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
4,087

Recommended

Rising costs and delayed production drive fair value cut for ASX iron ore player.

Jon Mills, CFA | 04 August 2026

Supply disruptions turbocharge refining profits and lift earnings forecasts for ASX energy share.

Mark Taylor | 04 August 2026

Pricing strength outweighs temporary production headwinds.

Mark Taylor | 03 August 2026

Index	Last price	Change	% Change
All Ordinaries	9,405.40	59.70	0.64%
CAC 40	8,669.30	2.67	0.03%
DAX 40	26,139.03	63.32	-0.24%
Dow JONES (US)	54,523.85	437.97	0.81%
FTSE 100	10,888.30	8.92	0.08%
HKSE	25,915.82	62.90	0.24%
NASDAQ	26,526.35	58.64	-0.22%
Nikkei 225	66,300.44	2,342.91	3.66%
NZX 50 Index	13,997.18	93.72	0.67%
S&P 500	7,737.97	1.45	0.02%
S&P/ASX 200	9,227.80	51.30	0.56%
SSE Composite Index	3,878.43	56.15	1.47%